Chemotherapy Can Affect Lung Cancer Response to Gefitinib
Chemotherapy-naive patients with non-small cell lung cancer (NSCLC) along with epidermal growth factor receptor mutations of the tyrosine kinase domain have greater responses to gefitinib than those who have received chemotherapy, according to Taiwanese researchers.
This entry was posted on Wednesday, November 19th, 2008 at 4:00 pm and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.